Home/Filings/8-K/0001213900-26-004674
8-K//Current report

Horizon Space Acquisition II Corp. 8-K

Accession 0001213900-26-004674

$HSPTCIK 0002032950operating

Filed

Jan 14, 7:00 PM ET

Accepted

Jan 15, 4:06 PM ET

Size

274.9 KB

Accession

0001213900-26-004674

Research Summary

AI-generated summary of this filing

Updated

Horizon Space Acquisition II Files 8-K: Proxy Update for SL Bio Merger

What Happened
Horizon Space Acquisition II Corp. (HSPT) filed a Current Report on Form 8-K (Jan 15, 2026) to correct and replace certain references and contact information contained in the definitive proxy statement it filed with the SEC on January 13, 2026. The proxy statement relates to HSPT’s proposed business combination with SL BIO Ltd. and an Extraordinary Meeting of HSPT shareholders scheduled for February 3, 2026. The 8-K clarifies the Trust Account trustee (Wilmington Trust, National Association), the transfer agent (VStock Transfer, LLC), and the proxy solicitor (Advantage Proxy, Inc.) contact details and procedures for obtaining materials and exercising redemption rights.

Key Details

  • Definitive Proxy Statement filed Jan 13, 2026; Form F-4 registration statement declared effective Jan 13, 2026; Extraordinary Meeting set for Feb 3, 2026.
  • Trust Account trustee: Wilmington Trust, National Association.
  • Transfer agent: VStock Transfer, LLC — 18 Lafayette Place, Woodmere, NY 11598; email: action@vstocktransfer.com; Attn: Action Team.
  • Proxy solicitor: Advantage Proxy, Inc., Attn: Karen Smith, Toll Free (877) 870-8565, Collect (206) 870-8565, ksmith@advantageproxy.com.
  • Redemption deadline: 5:00 pm ET on Jan 30, 2026 (two business days before the vote). Shareholders must deliver public shares (physically or electronically) to the transfer agent by that deadline; DWAC electronic delivery is recommended to avoid delays and costs (physical certificates can take weeks and may incur fees).

Why It Matters
The 8-K is an administrative correction but important for shareholders who need to request proxy materials or exercise redemption rights in connection with the SL Bio business combination. The filing reiterates the redemption mechanics: public shareholders can redeem shares for a pro rata cash amount from HSPT’s Trust Account, but must follow the transfer agent’s delivery and written-request procedures by the Jan 30 deadline. Significant redemptions could reduce cash available from the Trust Account, lower the number of shareholders and outstanding shares, potentially reduce liquidity in the post-merger public market, and affect the ability to meet Nasdaq listing requirements—facts the proxy statement highlights as material risks. There is no change to the proposals, record date, or meeting location (Robinson & Cole LLP, 666 Third Avenue, 20th Floor, New York, NY) or the teleconference dial-in (+1 813-308-9980, Access Code: 173547).